University of California San Francisco
Give to UCSF
Continuing a popular but controversial treatment for osteoporosis could reduce spine fracture risk for a particular group of patients, but others could see little to no change if they discontinue it, according to a researcher at UCSF.
<p>Academic medical centers can play a larger role in drug development and testing, according to an FDA official, who says there is a need for better strategies to identify winners, minimize costs and reduce failures during drug development.</p>
A popular smoking cessation medication has been under a cloud of suspicion ever since the Canadian Medical Association Journal published a study in July 2011 reporting “risk of serious adverse cardiovascular events associated with varenicline.” UCSF researchers, however, question the way the previous study was conducted, and their new analysis, scheduled to be published May 4 in BMJ, reaches a very different conclusion.
A UCSF-led effort to create an implantable artificial kidney for dialysis patients has been selected as one of the first projects to undergo more timely and collaborative review at the Food and Drug Administration.
The California Institute for Quantitative Biosciences (QB3) has renewed and expanded a three-year agreement with Pfizer Inc. to collaborate on research projects at the University of California with the potential to transform world-class science into better medicine.